NO20085374L - Anvendelse av fytat som middel for a inhibere opplosning av krystaller av kalsiumsalter for forhindring av osteoporose - Google Patents

Anvendelse av fytat som middel for a inhibere opplosning av krystaller av kalsiumsalter for forhindring av osteoporose

Info

Publication number
NO20085374L
NO20085374L NO20085374A NO20085374A NO20085374L NO 20085374 L NO20085374 L NO 20085374L NO 20085374 A NO20085374 A NO 20085374A NO 20085374 A NO20085374 A NO 20085374A NO 20085374 L NO20085374 L NO 20085374L
Authority
NO
Norway
Prior art keywords
crystals
calcium salts
phytate
supplements
dissolution
Prior art date
Application number
NO20085374A
Other languages
English (en)
Other versions
NO344167B1 (no
Inventor
Pilar Sanchis Cortes
Antonia Costa-Bauza
Joan Perello Bestard
Rafael Mara Prieto Almirall
Bernat Isern Amengual
Ramon Garcia Gonzalez
Original Assignee
Univ Illes Balears
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illes Balears filed Critical Univ Illes Balears
Publication of NO20085374L publication Critical patent/NO20085374L/no
Publication of NO344167B1 publication Critical patent/NO344167B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Foreliggende oppfinnelse refererer til anvendelsen av myo-inositolheksafosfat eller farmasøytisk akseptable salter derav for fremstilling av et medikament for forhindring eller behandling av en sykdom assosiert med oppløsning av krystaller av kalsiumsalter, særlig osteoporose. Nevnte forbindelse kan anvendes ved fremstilling av funksjonell mat, diettsupplementer, vitaminsupplementer, ernæringssupplementer eller matsupplementer eller fytoterapeutiske produkter som har egenskaper med å inhibere oppløsning av krystaller av kalsiumsalter.
NO20085374A 2006-06-01 2008-12-23 Anvendelse av fytat for forhindring/behandling av osteoporose NO344167B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200601519A ES2288126B2 (es) 2006-06-01 2006-06-01 Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
PCT/ES2007/070102 WO2007138147A1 (es) 2006-06-01 2007-05-30 Utilización de fitato como agente inhibidor de la disolución de cristales de sales cálcicas para la prevención de la osteoporosis

Publications (2)

Publication Number Publication Date
NO20085374L true NO20085374L (no) 2009-03-02
NO344167B1 NO344167B1 (no) 2019-09-23

Family

ID=38778157

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085374A NO344167B1 (no) 2006-06-01 2008-12-23 Anvendelse av fytat for forhindring/behandling av osteoporose

Country Status (13)

Country Link
US (1) US8377909B2 (no)
EP (1) EP2022501B1 (no)
JP (1) JP2009538883A (no)
CN (2) CN101484174A (no)
AU (1) AU2007266983B2 (no)
CA (1) CA2654281C (no)
DK (1) DK2022501T3 (no)
ES (2) ES2288126B2 (no)
MX (1) MX2008015205A (no)
NO (1) NO344167B1 (no)
PL (1) PL2022501T3 (no)
PT (1) PT2022501T (no)
WO (1) WO2007138147A1 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2332636B1 (es) * 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
US9364490B2 (en) 2013-03-15 2016-06-14 Laboratoris Sanifit, S.L. Use of derivatives containing C—O—P bonds in patients with kidney failure
EP3848053A1 (en) * 2015-12-11 2021-07-14 Universität Bern Inositol derivatives for use in pathological crystallization
US11707470B2 (en) 2015-12-11 2023-07-25 Eth Zurich Inositol derivatives for use in pathological crystallization
US11028112B2 (en) 2015-12-11 2021-06-08 Eth Zurich Inositol derivatives for use in pathological crystallization
DE102016013737A1 (de) 2016-11-17 2018-05-17 WindplusSonne GmbH Hexahydroxycyclohexanhexaphosphorsäureestersalze zur Behandlung von Kalzinose sowie diätische Lebensmittel mit Hexahydroxycyclohexanhexaphosphorsäureestersalzen als Zusatzstoffe
WO2019082335A1 (ja) * 2017-10-26 2019-05-02 大塚製薬株式会社 イノシトールリン酸含有組成物
CN112839661A (zh) 2018-10-11 2021-05-25 萨尼菲特治疗有限公司 用于治疗异位钙化的肌醇磷酸酯类
CA3130735A1 (en) 2019-01-30 2020-08-06 Sanifit Therapeutics, S.A. Inositol phosphate compounds for use in increasing tissular perfusion
EP3818983A1 (en) 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
EP4015494A1 (en) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Processes for the preparation of soluble salts of inositol phosphates
EP4036097A1 (en) 2021-01-29 2022-08-03 Sanifit Therapeutics S.A. Ip4-4,6 substituted derivative compounds
TW202412815A (zh) 2022-07-29 2024-04-01 西班牙商薩尼菲特治療公司 Ip5經取代化合物
WO2024023359A1 (en) 2022-07-29 2024-02-01 Sanifit Therapeutics, S.A. Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015634A (en) 1986-04-16 1991-05-14 Perstorp Ab Method of treating tissue damage with inositol triphosphate
US5057507A (en) 1986-04-16 1991-10-15 Perstorp Ab Method of alleviating bone damage with inositoltriphosphate
SE8904355D0 (sv) 1989-12-21 1989-12-21 Perstorp Ab Medicament
JP3320359B2 (ja) * 1998-06-09 2002-09-03 太子食品工業株式会社 有機態亜鉛を添加した食品
ES2152899B1 (es) * 1999-07-16 2002-03-16 Univ Illes Balears Aplicacion de harinas de germen de ciertos cereales en la fabricacion de productos alimenticios utiles para el tratamiento de estados carenciales en fitatos.
CN1120725C (zh) 1999-11-12 2003-09-10 高同祥 治疗骨质疏松、增生的药物及其制备方法
WO2004015084A2 (en) * 2002-08-12 2004-02-19 Genencor International, Inc. Mutant e. coli appa phytase enzymes
JP4595080B2 (ja) * 2003-09-25 2010-12-08 学校法人明治大学 セメント用材料およびセメント
ES2232302B1 (es) * 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
GB0517466D0 (en) * 2005-08-26 2005-10-05 Immunodiagnostic Systems Plc Diagnostic assay and therapeutic treatment
US20070212449A1 (en) 2006-03-02 2007-09-13 Shamsuddin Abulkalam M Reduction of the titratable acidity and the prevention of tooth and other bone degeneration
JP2007302600A (ja) * 2006-05-11 2007-11-22 Kaneka Corp イネ属植物材料由来の骨代謝改善用組成物とその製造方法

Also Published As

Publication number Publication date
CA2654281C (en) 2013-12-24
US20090203650A1 (en) 2009-08-13
MX2008015205A (es) 2009-03-12
CN101484174A (zh) 2009-07-15
US8377909B2 (en) 2013-02-19
PT2022501T (pt) 2019-11-06
JP2009538883A (ja) 2009-11-12
EP2022501A1 (en) 2009-02-11
CN103908455A (zh) 2014-07-09
WO2007138147A1 (es) 2007-12-06
ES2748108T3 (es) 2020-03-13
ES2288126A1 (es) 2007-12-16
ES2288126B2 (es) 2009-07-06
CA2654281A1 (en) 2007-12-06
DK2022501T3 (da) 2019-11-04
NO344167B1 (no) 2019-09-23
BRPI0711506A2 (pt) 2011-11-01
PL2022501T3 (pl) 2020-03-31
AU2007266983A1 (en) 2007-12-06
AU2007266983B2 (en) 2011-10-13
EP2022501A4 (en) 2009-11-11
EP2022501B1 (en) 2019-08-14

Similar Documents

Publication Publication Date Title
NO20085374L (no) Anvendelse av fytat som middel for a inhibere opplosning av krystaller av kalsiumsalter for forhindring av osteoporose
WO2011036316A3 (es) Uso de extractos vegetales como prebióticos, composiciones y alimentos que los contienen
FI20065593A0 (fi) Menetelmä galakto-oligosakkarideja sisältävien tuotteiden valmistamiseksi ja niiden käyttö
BR112012025943A2 (pt) compostos, composições e métodos para reduzir ou eliminar o sabor amargo.
BRPI0818079A8 (pt) Composição de lipídeo
WO2016019400A3 (en) Functional-gel compositions methods
MY184985A (en) Oligosaccharide mixture and food product comprising this mixture, especially infant formula
PH12014502811A1 (en) Dietary management of celiac disease and food allergy
WO2007113008A3 (en) Opaque container comprising food or pharmaceutical products or herbal(s)
WO2011163319A3 (en) Activation of amp-protein activated kinase by oxaloacetate compounds
WO2013058758A3 (en) Compounds, compositions, and methods for reducing or eliminating bitter taste
WO2008102017A3 (en) Food comprising polyunsaturated fatty acids for the prevention of chronic diseases
WO2007107008A8 (en) Compounds and compositions for use in the prevention and treatment of disorders of fat metabolism and obesity
WO2011009851A3 (en) Walnut extracts for nutraceutical applications
WO2011118957A3 (ko) 파프리카 추출물을 함유하는 염증, 알레르기 또는 천식 질환 치료용 조성물
EP2554057A4 (en) ENERAL OR ORAL FOOD PRODUCT SPECIALLY FOR NUTRITION, PREVENTION AND MITIGATION OF NEUROLOGICAL OR NEURODEGENERATIVE ALTERATIONS OR COGNITIVE DISORDERS
WO2011093599A3 (ko) 여성 갱년기 증상개선에 효과를 갖는 효모 가수분해물 및 이를 포함하는 식품
WO2007031140A3 (de) Extrakte aus epimedium-arten, verfahren zu ihrer herstellung und verwendung
JP2016520588A5 (no)
WO2016168868A3 (en) Compositions and methods to create natural curing foods
WO2008108284A1 (ja) Rankl産生抑制剤
WO2011061687A3 (en) Multiple-phase dietary supplement product
Bolland et al. 52 Calcium and Bone Metabolism
WO2009117160A4 (en) Compound and method for treatment of gastroesophageal reflux
MX2011002126A (es) Formulaciones farmaceuticas y/o nutraceuticas a base de curcumina y myo-inositol para controlar el proceso oxidativo e inflamatorio en enfermedades cronico-degenerativas.